This is a single site pilot trial will evaluate the feasibility and safety of fecal microbiota transplantation (FMT) in patients with B-cell lymphoma who are undergoing CAR-T or in patients with moderate to high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing allogeneic stem cell transplantation.
Men and women ≥ 18 years of age
Indolent or aggressive B-cell lymphoma eligible for standard or care CAR-T therapy (Cohort A), or
Patients with AML or high risk MDS with indication to undergo reduced-intensity conditioning alloSCT, with an available matched related, unrelated, or haploidentical donor (Cohort B)
ECOG 0-1
For patients undergoing alloSCT (Cohort B): plan to undergo myeloablative conditioning
Use of investigational agents within the last 4 weeks before enrollment.
Active or uncontrolled infection
Autoimmune disorder currently being treated with disease-modifying therapy or with >10mg/day prednisone